Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Koon Teo

Showing results (71-80 of 171) with videos related to

Pageof 18
Sort By:
BMJ Open Diabetes Research & Care|April 22, 2022
Serum metabolomic signatures of gestational diabetes in South Asian and white European womenClaudia Sikorski, Sandi Azab, Russell J de Souza, et al.
JAMA|November 24, 2011
Urinary sodium and potassium excretion and risk of cardiovascular eventsMartin J O'Donnell, Salim Yusuf, Andrew Mente, et al.
Journal of the American College of Cardiology|December 24, 2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)Josep Redon, Giuseppe Mancia, Peter Sleight, et al.
European Heart Journal|November 30, 2013
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges, Salim Yusuf, Amir Attaran, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Circulation|March 17, 2010
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) TrialsMichael Böhm, Magnus Baumhäkel, Koon Teo, et al.
Nature Medicine|July 1, 2026
A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trialsQianqian Yang, Zeinab Bidel, Dexter Canoy, et al.
European Heart Journal|December 24, 2010
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk ScoreCatherine McGorrian, Salim Yusuf, Shofiqul Islam, et al.
Plos One|September 14, 2012
Environmental Profile of a Community's Health (EPOCH): an ecometric assessment of measures of the community environment based on individual perceptionDaniel J Corsi, S V Subramanian, Martin McKee, et al.
The Lancet. Neurology|October 29, 2010
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studiesCraig Anderson, Koon Teo, Peggy Gao, et al.
Pageof 18

Showing results (71-80 of 171) with videos related to

Sort By:
Pageof 18
BMJ Open Diabetes Research & Care|April 22, 2022
Serum metabolomic signatures of gestational diabetes in South Asian and white European womenClaudia Sikorski, Sandi Azab, Russell J de Souza, et al.
JAMA|November 24, 2011
Urinary sodium and potassium excretion and risk of cardiovascular eventsMartin J O'Donnell, Salim Yusuf, Andrew Mente, et al.
Journal of the American College of Cardiology|December 24, 2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)Josep Redon, Giuseppe Mancia, Peter Sleight, et al.
European Heart Journal|November 30, 2013
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges, Salim Yusuf, Amir Attaran, et al.
Circulation. Cardiovascular Quality and Outcomes|May 13, 2018
Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Zugui Zhang, Philip Jones, William S Weintraub, et al.
Circulation|March 17, 2010
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) TrialsMichael Böhm, Magnus Baumhäkel, Koon Teo, et al.
Nature Medicine|July 1, 2026
A meta-analysis of the long-term effects of antihypertensive therapy on the risk of major cardiovascular disease across 51 randomized trialsQianqian Yang, Zeinab Bidel, Dexter Canoy, et al.
European Heart Journal|December 24, 2010
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk ScoreCatherine McGorrian, Salim Yusuf, Shofiqul Islam, et al.
Plos One|September 14, 2012
Environmental Profile of a Community's Health (EPOCH): an ecometric assessment of measures of the community environment based on individual perceptionDaniel J Corsi, S V Subramanian, Martin McKee, et al.
The Lancet. Neurology|October 29, 2010
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studiesCraig Anderson, Koon Teo, Peggy Gao, et al.
Pageof 18